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The thieno[2,3-d]pyrimidinedione core is found as a component in a range of pharmaceutically active
compounds, however, synthetic approaches to these scaffolds rely on access to functionalised, highly
substituted thiophenes. Here we describe a new approach for the preparation of 5-carboxamide-6-aryl
analogues that involves a two-step synthesis of the thieno[2,3-d]pyrimidinedione core from a readily
available mercaptouracil derivative. Thio-alkylation with ethyl 3-bromopyruvate, followed by cyclisation
and dehydration mediated by polyphosphoric acid allowed the scalable synthesis of the thieno[2,3-d]
pyrimidinedione unit. The late-stage functionalisation of this core motif via bromination of the thio-
phene ring and a subsequent Suzuki-Miyaura reaction as the key steps permitted access to a novel library
of 5-carboxamide-6-aryl analogues. The physicochemical properties of these compounds were deter-
mined, generating an insight into the potential bioavailability of these scaffolds. Based on these results, a
selection of the novel 5-carboxamide-6-aryl analogues were tested as lactate uptake inhibitors of
monocarboxylate transporters 1, 2 and 4 in Xenopus oocytes.
© 2018 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Due to their similarity in structure to nucleic acid bases, pyrrolo
[2,3-d]pyrimidine and thieno[2,3-d]pyrimidine scaffolds display a
wide range of biological activities [1]. Within this structural class,
the thieno[2,3-d]pyrimidinediones have been of particular interest,
with pharmaceutical activity against a wide range of disease states.
For example, thieno[2,3-d]pyrimidinediones bearing a N-piper-
azinylethyl moiety such as 1 (Fig. 1) are potent oral antihyperten-
sive agents that can reduce systolic blood pressure [2]. In a
programme to discover new inhibitors of the monocarboxylate
transporter 1, AstraZeneca showed that thieno[2,3-d]pyr-
imidinediones with 5-carboxamide-6-alkyl substituents had
potent immunomodulatory activity [3]. More recently, compounds
from this series (e.g. AZD3965 2) have been shown to kill tumour
cells reliant on glycolysis [4]. Other examples include thieno[2,3-d](A. Sutherland).
ier Ltd. This is an open access articpyrimidinediones with a 6-(p-methoxyureidophenyl) substituent,
such as relugolix 3 [5]. These compounds are selective antagonists
of the gonadotropin-releasing hormone receptor and are in phase 3
clinical trials for the treatment of endometrosis and prostrate
cancer [6,7].
Despite the importance of thieno[2,3-d]pyrimidinediones, there
are relatively few synthetic approaches that allow both the efficient
preparation of the bicyclic core and further functionalisation of
either ring. Common approaches to access thieno[2,3-d]pyr-
imidinediones include the reaction of 2-aminothiophenes with
isocyanates [2,5] or the alkylation of mercaptouracil derivatives
with a-halocarbonyl compounds, followed by cyclisation in the
presence of Lewis acids such as titanium tetrachloride [3c,8,9].
Building on our research programme that seeks to discover
novel biologically active polycyclic scaffolds [10], we were inter-
ested in developing a scalable synthesis of a thieno[2,3-d]pyr-
imidinedione core that could then be further functionalised
allowing late stage access to a diverse series of highly substituted
analogues. We now report a three-stage synthetic approach for thele under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Fig. 1. Pharmaceutically active thieno[2,3-d]pyrimidinediones.
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imidinedione-5-carboxamide-6-aryl analogues. We have deter-
mined various physicochemical properties of these compounds,
highlighting the potential of this scaffold for medicinal chemistry
applications. The ability of these novel thieno[2,3-d]pyr-
imidinedione-5-carboxamide-6-aryl analogues to inhibit lactate
uptake of monocarboxylate transporters 1, 2 and 4 in Xenopus oo-
cytes is also presented.2. Results and discussion
As outlined in Scheme 1, a three-stage approach was proposed
for the preparation of the target thieno[2,3-d]pyrimidinedione-5-
carboxamide-6-aryl analogues. The first-stage involved the devel-
opment of a reproducible, scalable synthesis of thieno[2,3-d]pyr-
imidinedione 5 from commercially available 6-chloro-3-
methyluracil (4). The aim was then to investigate the reactivity of
this scaffold for the introduction of aryl groups at the 6-position.
Finally, as thieno[2,3-d]pyrimidinediones bearing a 5-carboxamide
moiety are often biologically active [1b,3], strategies for rapid
conversion of the thiophene-carboxylate ester to various carbox-
amide groups were then explored.
To investigate various thiophene-forming reactions, 6-
mercaptopyrimidinedione 7 was chosen as the key substrate. ThisScheme 1. Proposed approach to novel thieno[2,3-d]pyrimidinedione-5-carboxamide-
6-aryl analogues from 6-chloro-3-methyluracil (4).was prepared in two steps from 6-chloro-3-methyluracil (4), by N-
alkylation with isobutyl bromide under standard base-mediated
conditions, followed by an efficient substitution reaction with so-
dium hydrosulfide (Scheme 2).
Previous reactions using mercaptopyrimidinedione 7 for the
preparation of analogues of thieno[2,3-d]pyrimidinedione 5 have
utilised a two-stage process involving S-alkylation with 2-
chlorocarbonyl compounds followed by cyclisation and dehydra-
tion with titanium tetrachloride [3a,c]. However, these approaches
generally result in low overall yields (18e37%) [3a,c]. We attempted
a similar transformation with 7 and ethyl 3-bromopyruvate.
Although the S-alkylated intermediate 8was formed cleanly (by 1H
NMR spectroscopy), cyclisation and dehydration with titanium
tetrachloride gave only a 24% overall yield of thieno[2,3-d]pyr-
imidinedione 5 (Table 1, entry 1). In addition, it was difficult to
reproduce these results using this two-stage process. As a conse-
quence of the poor yields and reproducibility of using titanium
tetrachloride to form the thiophene ring, other methods were
investigated. Thieno[2,3-d]pyrimidinediones have been prepared
efficiently frommercaptopyrimidinedione 7, by deprotonationwith
sodium acetate, followed by reaction with a-halocarbonyl com-
pounds [11]. However, application of this method with 7 and ethyl
3-bromopyruvate gave only a 10% yield of 5, as well as a number of
side-products (entry 2) [12].
Ogura and co-workers demonstrated that mercaptopyr-
imidinediones could undergo S-alkylation with simple a-hal-
ocarbonyl compounds such as bromoacetone under neutral
conditions [9]. Following isolation and purification of the S-alky-
lated mercaptopyrimidinediones, subsequent cyclisation with pol-
yphosphoric acid (PPA) gave the corresponding thieno[2,3-d]
pyrimidinediones in good yields. Using this approach as a starting
point, conditions for the reaction of mercaptopyrimidinedione 7
with the highly electrophilic ethyl 3-bromopyruvate to form ester-
derived thieno[2,3-d]pyrimidinedione 5 were investigated. Reac-
tion of 7 with ethyl 3-bromopyruvate under neutral conditions did
form intermediate 8 cleanly (Table 1, entry 3). However, unlike the
alkyl and aryl derived intermediates from the Ogura study [12], S-
alkylated mercaptopyrimidinedione 8 could not be isolated and
purified due to significant decomposition. Therefore, intermediate
8 was directly converted to ester-derived thieno[2,3-d]pyr-
imidinedione 5 using the PPA-mediated cyclisation reaction.
Initially, the cyclisation step was found to proceed at 100 C,
generating thieno[2,3-d]pyrimidinedione 5 in modest yield (entry
3). Optimisation of this step included increasing the reaction tem-
perature, resulting in shorter reaction times. At an optimal tem-
perature of 145 C, this gave 5 in 54% overall yield from the one-pot,
two step procedure (entry 5) [13]. More importantly, this approach
was found to be readily reproducible and could be used for the
multigram synthesis of 5.
The next stage of this research programme involved aryl sub-
stitution of the 6-position of thieno[2,3-d]pyrimidinedione 5. A
two-step strategy was proposed involving bromination of the
thiophene ring, followed by a Suzuki-Miyaura reaction (Scheme 3)
[14]. Bromination of 5 under standard conditions with N-Scheme 2. Two-step synthesis of 6-mercaptopyrimidinedione 7.
Table 1
Optimisation of the synthesis of thieno[2,3-d]pyrimidinedione 5.
Entry Step 1 Step 2 Yield (%) of 5a
1 K2CO3, DMF, rt, 16 h TiCl4, CH2Cl2, 0 C to rt, 16 h 24%
2 NaOAc, H2O, rt, 5 h 60 C, 48 h 10%
3 EtOH, rt, 1 h PPA, 100 C, 12 h 35%
4 EtOH, rt, 1 h PPA, 130 C, 6 h 41%
5 EtOH, rt, 1 h PPA, 145 C, 3 h 54%
a Isolated yield over the two steps.
Scheme 3. Bromination and Suzuki-Miyaura reaction of thieno[2,3-d]pyr-
imidinedione-5-carboxylate ester 5.
Scheme 4. Preparation of the thieno[2,3-d]pyrimidinedione 5-carboxamide-6-aryl li-
brary. Isolated yields of 14e25 over the three steps are shown. a Hünig's base was also
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corresponding bromide 9 in 84% yield. Suzuki-Miyaura reaction of 9
was then performed with various boronic acids using Pd(PPh3)4 as
the catalyst. To explore the electronic and steric limitations of this
process, both electron-rich and electron-deficient phenylboronicacids bearing either ortho- or para-substituents were investigated.
Despite the variations, consistently high yields were observed for
all four analogues formed from this reaction.
Having demonstrated efficient functionalisation of the C-6 po-
sition of the thieno[2,3-d]pyrimidinedione core through incorpo-
ration of various aryl groups, the final stage required preparation of
the C-5 carboxamide. Initial studies began with the synthesis of
morpholine carboxamide 14 (Scheme 4). Rapid hydrolysis of ethyl
ester 10was achieved using sodium hydroxide in ethanol. Coupling
of the resulting carboxylic acid with morpholine was then
attempted using various standard coupling reagents (EDCI, HBTU
and EDCI/HOBt), however, all of these reactions gave low yields
(9e32%) of 14. It was proposed that the low yields were due to the
steric hindrance associated with the highly substituted thiophene
ring and the subsequent slow reaction with the bulky coupling
agents. It was believed that this could be overcome by using a
smaller and more reactive acid chloride intermediate. Therefore,
the carboxylic acid was converted to the acid chloride under mild
conditions using oxalyl chloride and DMF. Without purification,
this was treated with morpholine, resulting in the isolation of
carboxamide 14 in 48% yield over the three steps (Scheme 4).
Following the development of a straightforward approach to access
the thieno[2,3-d]pyrimidinedione-5-carboxamide-6-aryl scaffold,
the scope of this three step transformation was explored with
structurally different amines, for the formation of carboxamides
bearing cyclic and acyclic groups. As Weinreb amides are
commonly biologically active due to an ability to hydrogen bond to
biological targets [3], a series of these were also formed. Overall, allused for the amidation step.
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three step sequence to the corresponding carboxamides. Yields
were generally good for preparation of the morpholine carbox-
amides 14e17 and the Weinreb amides 22e25. Lower yields were
observed over the three steps for the diethyl carboxamide ana-
logues 18e21. In comparison to the other amines, this is likely due
to the less rigid and less reactive nature of diethylamine.
With the successful synthesis of a library of novel thieno[2,3-d]
pyrimidinedione-5-carboxamides, we were interested in evalu-
ating how the incorporation of aryl groups at the C-6 position
might affect the physicochemical properties. For compounds that
might find application in binding to neurological receptors by
penetrating the blood brain barrier, permeability across the plasma
membrane is important. Similarly, for compounds that transport
across cell membranes through passive diffusion, evaluation of the
membrane partition coefficient is crucial. Therefore, the partition
coefficient (log P), permeability (Pm), the membrane partition co-
efficient (Km) and the percentage of plasma protein binding (%PPB)
of all twelve thieno[2,3-d]pyrimidinedione-5-carboxamides were
evaluated using established HPLCmethods (Table 2). Previous work
by Tavares et al., of ten biologically active compounds, established
the limits of each of these parameters (log P< 4, Pm< 0.5, Km< 250,
%PPB< 95%) [15]. Based on these criteria, the physicochemical
properties of the majority of these compounds were found to be
excellent and well within the acceptable limits. Despite the incor-
poration of an aryl moiety and the resulting increase in lip-
ophilicity, these compounds possess properties that should allow
effective transport through cell membranes. Due to the relatively
lipophilic diethyl carboxamide group, compounds 18 and 19 were
found to have the highest plasma protein binding (%PPB). While
these values are above the acceptable limit, there are medicinally
important compounds with similar plasma protein binding that
still demonstrate good bioavailability [13]. Therefore, all of these
structural classes are of interest for further development.
As highlighted above, thieno[2,3-d]pyrimidinediones have sig-
nificant biological activity, particularly against monocarboxylate
transporters (MCT), with certain compounds showing potent
immunomodulatory activity or the ability to kill tumour cells that
rely on glycolysis [3,4]. For these reasons, a selection of nine of the
thieno[2,3-d]pyrimidinediones prepared in this current study were
tested as inhibitors of lactate uptake of MCT1, MCT2 or MCT4 in
Xenopus oocytes (Fig. 2) [16]. As well as control (blank) experi-
ments, AR-C155858 (AR-C in Fig. 2), a commercially available in-
hibitor of MCTs was also tested as a standard [3c].While none of the
compounds showed any reduction in lactate uptake against MCT1,
morpholine carboxamide 15 showed significant activity against
MCT2 (p 0.01). For several of the compounds, a tendency toTable 2
Physicochemical values of compounds 14e25.
Entry Compound Log Pa Pmb Kmb %PPBc
1 14 3.02 0.12 51.74 87.8
2 15 2.97 0.17 77.39 93.2
3 16 2.94 0.18 82.00 90.5
4 17 2.87 0.16 75.01 92.4
5 18 3.67 0.44 189.16 95.8
6 19 3.63 0.42 181.54 96.4
7 20 3.69 0.25 111.51 90.5
8 21 4.22 0.33 147.24 93.4
9 22 3.38 0.23 96.05 87.8
10 23 3.32 0.17 69.68 88.2
11 24 3.52 0.20 88.19 88.4
12 25 3.53 0.18 76.75 86.3
Determined using:
a C18 column.
b Immobilised artificial membrane (IAM) column.
c Human serum albumin (HSA) coated column.
Fig. 2. Inhibition of lactate uptake in Xenopus oocytes, expressing (A) MCT1, (B)
MCT2 þ GP70 and (C) MCT4. Each compound was tested at a concentration of 1 mM.
The lactate uptake for each compound shown is the mean ± SEM of eight independent
experiments (n ¼ 8). The asterisks refer to the values of control cells (white bars).
*p  0.05, ***p  0.001.inhibit MCT2 was also observed, however the reduction in trans-
port activity did not significantly differ from the control cells. The
morpholine carboxamides also showed a slight inhibitory effect on
MCT4, with compounds 14 and 16 showing ~10% reduction in up-
take. Although these compounds are not significantly active in
inhibiting lactate uptake (each compound was tested at 1 mM), this
study has demonstrated the structure activity relationship of this
series and identified thieno[2,3-d]pyrimidinedione morpholine
carboxamide derivatives as potential scaffolds for further devel-
opment as lactate uptake inhibitors of MCTs.
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In summary, a flexible and concise approach for the preparation
of novel thieno[2,3-d]pyrimidinedione scaffolds has been devel-
oped. In particular, a reliable and scalable route for the synthesis of
a thieno[2,3-d]pyrimidinedione core bearing a C-5 ester moiety has
been achieved from a mercaptouracil derivative by an alkylation
reactionwith ethyl 3-bromopyruvate followed by an acid-mediated
cyclisation. The product of this process has served as a key inter-
mediate to explore the introduction of aryl groups at the C-6 po-
sition via bromination and a Suzuki-Miyaura reaction. Despite the
highly substituted nature of the thiophene ring, transformation of
the C-6 substituted esters to the corresponding amides was readily
achieved via the formation of acid chlorides under mild conditions.
Determination of several important physicochemical properties of
this small library of thieno[2,3-d]pyrimidinedione-5-carboxamide-
6-aryl analogues showed that despite the introduction of aryl units,
the majority of these compounds still retain the potential ability to
transport through cell membranes. Finally, a selection of com-
pounds prepared in this study was tested for the ability to inhibit
lactate uptake against various monocarboxylate transporters, with
the morpholine carboxamide analogues showing most activity.
Work is currently underway to further develop this class of thieno
[2,3-d]pyrimidinediones for a range of biological applications, as
well as explore further synthetic applications of this functionally
rich bicyclic core.
4. Experimental section
4.1. General methods
All reactions were performed under an atmosphere of air unless
otherwise stated. All reagents and starting materials were obtained
from commercial sources unless otherwise stated. Brine refers to a
saturated solution of sodium chloride. All dry solvents were puri-
fied using a PureSolv 500 MD solvent purification system. Flash
column chromatographywas carried out usingMerck Feduran Si 60
(40e63 mm). Macherey-Nagel aluminium-backed plates pre-coated
with silica gel 60 were used for thin layer chromatography and
were visualised under a UV lamp. 1H NMR and 13C NMR spectra
were recorded on a Bruker DPX 400 spectrometer or Bruker 500
spectrometer with chemical shift values in ppm relative to trime-
thylsilane or residual chloroform as standard. J values are reported
in Hz. The assignment of 1H NMR spectra is based on COSY and
HSQC experiments and 13C NMR spectra is based on DEPT experi-
ments. Infrared spectra were recorded using a Shimadzu FTIR-
84005 spectrometer directly as either a solid or liquid and mass
spectra were obtained using a JEOL JMS-700 spectrometer or a
Bruker MicroTOFq high-resolution mass spectrometer. Melting
points were determined on a Gallenkamp melting point apparatus.
All physicochemical analyses were performed using a Dionex Ul-
timate 3000 series, and data acquisition and processing performed
using Chromeleon 6.8 Chromatography software [14]. Standard and
test compounds were dissolved in 1:1 organic/aqueous phases, and
prepared to a concentration of 0.5mg/mL. The HPLC systemwas set
to 25 C, and UV detection achieved using a diode array detector
(190e800 nm). Analysis was performed using 5 mL sample
injections.
4.2. Experimental procedures and compound characterisation
4.2.1. 6-Chloro-3-methyl-1-(20-methylpropyl)-2,4-(1H,3H)-
pyrimidinedione (6) [17]
Isobutyl bromide (8.90mL, 82.2mmol) was added to a solution
of 6-chloro-3-methyluracil (4) (12.0 g, 74.7mmol) and potassiumcarbonate (12.4 g, 89.7mmol) in DMSO (120mL). The mixture was
then heated to 60 C and stirred for 48 h. The mixture was then
cooled to room temperature and diluted with water (40mL) and
brine (40mL). The product was then extracted using diethyl ether
(3 40mL). The organic layers were combined, dried (MgSO4),
filtered and concentrated in vacuo to provide title compound 6
(13.7 g, 84%) as an orange oil. This was used directly in the next step
without further purification. Spectroscopic data were consistent
with the literature.17 1H NMR (400MHz, CDCl3) d 0.96 (6H, d,
J¼ 6.8 Hz, CH(CH3)2), 2.11e2.22 (1H, m, 20-H), 3.34 (3H, s, 3-CH3),
3.90 (2H, d, J¼ 7.6 Hz, 10-H2), 5.92 (1H, s, 5-H); 13C NMR (101MHz,
CDCl3) d 19.7 (2 CH3), 28.1 (CH3), 28.3 (CH), 53.5 (CH2), 101.9 (CH),
146.0 (C),151.2 (C),160.9 (C); MS (CI)m/z 217 (MþHþ, 95%),183 (17),
69 (10).4.2.2. 6-Mercapto-3-methyl-1-(20-methylpropyl)-2,4-(1H,3H)-
pyrimidinedione (7) [3a]
Sodium hydrosulfide monohydrate (1.28 g, 22.7mmol) was
added to a stirred solution of 6-chloro-3-methyl-1-(20-methyl-
propyl)-2,4-(1H,3H)-pyrimidinedione (6) (4.10 g, 18.9mmol) in
ethanol (60mL). The mixture was stirred at room temperature for
24 h before further sodium hydrosulfide monohydrate (1.28 g,
22.7mmol) was added and stirring continued at room temperature
for a further 16 h under an atmosphere of argon. The solution was
concentrated in vacuo and the resulting oil diluted with water
(30mL) and washed with ethyl acetate (30mL). The aqueous layer
was then acidified with an aqueous solution of 1M hydrochloric
acid and then extracted using ethyl acetate (3 30mL). The com-
bined organic layers were then dried (MgSO4), filtered and
concentrated in vacuo to give 6-mercapto-3-methyl-1-(20-methyl-
propyl)-2,4-(1H,3H)-pyrimidinedione (7) as a pale yellow solid
(3.69 g, 90%). Spectroscopic datawere consistent with the literature
[3a]. Mp 111e113 C; 1H NMR (400MHz, CDCl3) d 0.92 (6H, d,
J¼ 6.8 Hz, CH(CH3)2), 2.24e2.31 (1H, m, 20-H), 3.29 (3H, s, 3-CH3),
4.14 (2H, s, 5-H2), 4.27 (2H, d, J¼ 7.4 Hz, 10-H2); 13C NMR (101MHz,
CDCl3) d 20.1 (2 CH3), 26.6 (CH3), 28.6 (CH), 49.2 (CH2), 54.5 (CH2),
150.3 (C), 164.8 (C), 197.2 (C); MS (ESI) m/z 237 (MþNaþ, 60%), 159
(20), 307 (5), 449 (2).4.2.3. Ethyl 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (5) [3a]
Ethyl bromopyruvate (1.70mL, 13.3mmol) was added to a so-
lution of 6-mercapto-1-isobutyl-3-methyl-2,4-(1H,3H)-pyr-
imidinedione (7) (1.90 g, 8.87mmol) in ethanol (40mL) and stirred
at room temperature for 1 h. The reaction mixture was concen-
trated in vacuo to give a red oil. A mixture of the crude intermediate
and polyphosphoric acid (10.0 g) were heated to 145 C for 3 h, and
then cooled to room temperature. A saturated aqueous solution of
sodium carbonate (15mL) was added and the mixture extracted
with ethyl acetate (3 25mL). The combined organic layers were
dried (MgSO4), filtered and concentrated in vacuo. Purification by
flash column chromatography eluting with 20% ethyl acetate in
petroleum ether gave ethyl 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (5) as a dark pink
solid (1.46 g, 54%). Mp 62e66 C. Spectroscopic data were consis-
tent with the literature [3a]. 1H NMR (400MHz, CDCl3) d 1.00 (6H, d,
J¼ 6.9 Hz, CH(CH3)2), 1.40 (3H, t, J¼ 7.4 Hz, OCH2CH3), 2.26e2.38
(1H, m, 20-H), 3.42 (3H, s, 3-CH3), 3.81 (2H, d, J¼ 7.6 Hz, 10-H2), 4.41
(2H, q, J¼ 7.4 Hz, OCH2CH3), 7.29 (1H, s, 6-H); 13C NMR (101MHz,
CDCl3) d 14.2 (CH3), 20.0 (2 CH3), 27.0 (CH), 28.5 (CH3), 56.2 (CH2),
61.9 (CH2), 112.6 (C), 119.4 (CH), 132.3 (C), 150.8 (C), 154.2 (C), 157.0
(C), 162.9 (C); MS (ESI) m/z 333 (MþNaþ, 100%).
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tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (9)
N-Bromosuccinimide (0.598 g, 3.36mmol) was added to a stir-
red solution of ethyl 1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (5) (0.870 g,
2.80mmol) in dichloromethane (15mL) and acetic acid (15mL) and
stirred at room temperature for 5 h. The reaction mixture was
azeotroped under vacuum in the presence of toluene (3 30mL).
Purification by flash column chromatography eluting with 20%
ethyl acetate in petroleum ether gave ethyl 6-bromo-1-isobutyl-3-
methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-
carboxylate (9) as a white solid (0.911 g, 84%). Mp 110e114 C; IR
(neat) 2961 (CH), 1736 (CO), 1707 (CO), 1661 (CO), 1481, 1283,
1238 cm1; 1H NMR (400MHz, CDCl3) d 0.99 (6H, d, J¼ 6.7 Hz,
CH(CH3)2),1.42 (3H, t, J¼ 7.1 Hz, OCH2CH3), 2.24e2.33 (1H, m, 20-H),
3.40 (3H, s, 3-CH3), 3.72 (2H, d, J¼ 7.8 Hz, 10-H2), 4.48 (2H, q,
J¼ 7.1 Hz, OCH2CH3); 13C NMR (101MHz, CDCl3) d 14.1 (CH3), 20.0
(2 CH3), 27.0 (CH), 28.4 (CH3), 56.5 (CH2), 62.6 (CH2), 103.5 (C),
113.1 (C), 132.5 (C), 150.5 (C), 153.2 (C), 156.4 (C), 162.7 (C); MS (ESI)
m/z 411 (MþNaþ, 100%); HRMS (ESI) calcd for C14H1779BrN2NaO4S
(MþNaþ), 410.9985, found 410.9972.
4.2.5. Ethyl 6-(400-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (10)
Potassium phosphate (0.18 g, 0.78mmol) was suspended in a
solution of ethyl 6-bromo-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (9) (0.15 g,
0.39mmol) and 4-fluorophenylboronic acid (0.070 g, 0.50mmol) in
N,N0-dimethylformamide (10mL) and degassed for 1 h. Tetrakis(-
triphenylphosphine)palladium(0) (0.045 g, 0.039mmol) was added
and the reaction heated under reflux for 22 h. The reaction mixture
was cooled to room temperature, extracted into ethyl acetate
(30mL) and washed with an aqueous solution of 5% lithium chlo-
ride (4 25mL) and brine (2 20mL). The organic layers were
combined, dried (MgSO4), filtered and concentrated in vacuo. Pu-
rification by flash column chromatography eluting with 20% ethyl
acetate in petroleum ether gave ethyl 6-(400-fluorophenyl)-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]py-
rimidine-5-carboxylate (10) as a white solid (0.13 g, 81%). Mp
143e145 C; IR (neat) 2963 (CH), 1732 (CO), 1707 (CO), 1663 (CO),
1537, 1483, 1294, 1206 cm1; 1H NMR (400MHz, CDCl3) d 1.02 (6H,
d, J¼ 7.0 Hz, CH(CH3)2), 1.30 (3H, t, J¼ 7.3 Hz, OCH2CH3), 2.30e2.40
(1H, m, 20-H), 3.42 (3H, s, 3-CH3), 3.81 (2H, d, J¼ 7.7 Hz, 10-CH2),
4.38 (2H, q, J¼ 7.3 Hz, OCH2CH3), 7.01e7.13 (2H, m, 200-H and 600-H),
7.46e7.51 (2H, m, 300-H and 500-H); 13C NMR (101MHz, CDCl3) d 14.0
(CH3), 20.0 (2 CH3), 27.1 (CH3), 28.3 (CH), 56.4 (CH2), 62.3 (CH2),
114.0 (C), 116.2 (d, 2JCF¼ 22.3 Hz, 2 CH), 127.2 (d, 4JCF¼ 3.8 Hz, C),
128.1 (C), 129.0 (C), 130.2 (d, 3JCF¼ 9.8 Hz, 2 CH), 150.7 (C), 152.3
(C), 157.5 (C),162.8 (d, 1JCF¼ 250.7 Hz, C),167.7 (C); MS (ESI)m/z 427
(MþNaþ, 100%); HRMS (ESI) calcd for C20H21FN2NaO4S (MþNaþ),
427.1098, found 427.1093.
4.2.6. Ethyl 6-(200-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (11)
The reaction was carried out according to the previously
described procedure for compound 10 using ethyl 6-bromo-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]py-
rimidine-5-carboxylate (9) (0.20 g, 0.51mmol) and 2-
fluorophenylboronic acid (0.11 g, 0.67mmol). This gave title com-
pound 11 as a light pink solid (0.18 g, 86%). Mp 94e98 C; IR (neat)
2963 (CH), 1732 (CO), 1707 (CO), 1661 (CO), 1487, 1223, 1018,
758 cm1; 1H NMR (400MHz, CDCl3) d 1.01 (6H, d, J¼ 7.3 Hz,
CH(CH3)2),1.26 (3H, t, J¼ 7.1 Hz, OCH2CH3), 2.30e2.40 (1H, m, 20-H),
3.42 (3H, s, 3-CH3), 3.82 (2H, d, J¼ 7.5 Hz, 10-CH2), 4.35 (2H, q,
J¼ 7.1 Hz, OCH2CH3), 7.13e7.18 (1H, m, 300-H), 7.20 (1H, td, J¼ 7.8,1.2 Hz, 500-H), 7.36e7.42 (1H, m, 600-H), 7.51 (1H, td, J¼ 7.8, 1.6 Hz,
400-H); 13C NMR (101MHz, CDCl3) d 14.0 (CH3), 20.1 (2 CH3), 27.0
(CH3), 28.3 (CH), 56.3 (CH2), 62.1 (CH2), 113.4 (C), 116.1 (d,
2JCF¼ 21.7 Hz, CH), 118.9 (d, 2JCF¼ 15.1 Hz, C), 124.5 (d, 4JCF¼ 3.9 Hz,
CH), 126.2 (C), 129.7 (C), 131.1 (d, 3JCF¼ 8.0 Hz, CH), 131.1 (d,
3JCF¼ 9.8 Hz, CH), 150.7 (C), 153.4 (C), 157.4 (C), 159.5 (d,
1JCF¼ 251.9 Hz, C), 164.1 (C); MS (ESI) m/z 427 (MþNaþ, 100%);
HRMS (ESI) calcd for C20H21FN2NaO4S (MþNaþ), 427.1098, found
427.1087.
4.2.7. Ethyl 1-isobutyl-6-(400-methoxyphenyl)-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (12)
The reaction was carried out according to the previously
described procedure for compound 10 using ethyl 6-bromo-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]py-
rimidine-5-carboxylate (9) (0.20 g, 0.51mmol) and 4-
methoxyphenylboronic acid (0.10 g, 0.67mmol). This gave title
compound 12 as a white solid (0.18 g, 85%). Mp 129e131 C; IR
(neat) 2961 (CH), 1730 (CO), 1705 (CO), 1659 (CO), 1537, 1483, 1294,
1252, 1204, 1020, 831, 729 cm1; 1H NMR (400MHz, CDCl3) d 1.01
(6H, d, J¼ 6.7 Hz, CH(CH3)2), 1.31 (3H, t, J¼ 7.3 Hz, OCH2CH3),
2.30e2.40 (1H, m, 20-H), 3.41 (3H, s, 3-CH3), 3.80 (2H, d, J¼ 7.7 Hz,
10-CH2), 3.84 (3H, s, 400-OCH3), 4.39 (2H, q, J¼ 7.3 Hz, OCH2CH3),
6.92 (2H, d, J¼ 8.8 Hz, 300-H and 500-H), 7.43 (2H, d, J¼ 8.8 Hz, 200-H
and 600-H); 13C NMR (101MHz, CDCl3) d 14.0 (CH3), 20.0 (2 CH3),
27.1 (CH3), 28.3 (CH), 55.4 (CH3), 56.3 (CH2), 62.2 (CH2), 114.0 (C),
114.4 (2 CH), 123.5 (C), 126.2 (C), 129.5 (2 CH), 132.9 (C), 150.8
(C), 151.8 (C), 157.6 (C), 160.3 (C), 165.0 (C); MS (ESI) m/z 439
(MþNaþ, 100%); HRMS (ESI) calcd for C21H24N2NaO5S (MþNaþ),
439.1298, found 439.1283.
4.2.8. Ethyl 1-isobutyl-6-(200-methoxyphenyl)-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (13)
The reaction was carried out according to the previously
described procedure for compound 10 using ethyl 6-bromo-1-
isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]py-
rimidine-5-carboxylate (9) (0.20 g, 0.51mmol) and 2-
methoxyphenylboronic acid (0.10 g, 0.67mmol). This gave title
compound 13 as a yellow solid (0.18 g, 86%). Mp 119e123 C; IR
(neat) 2963 (CH), 1730 (CO), 1705 (CO), 1659 (CO), 1489, 1479, 1244,
1200, 1020, 729 cm1; 1H NMR (400MHz, CDCl3) d 1.01 (6H, d,
J¼ 6.3 Hz, CH(CH3)2), 1.23 (3H, t, J¼ 7.3 Hz, OCH2CH3), 2.31e2.41
(1H, m, 20-H), 3.42 (3H, s, 3-CH3), 3.81 (2H, d, J¼ 7.8 Hz, 10-CH2),
3.84 (3H, s, 200-OCH3), 4.32 (2H, q, J¼ 7.3 Hz, OCH2CH3), 6.95 (1H, br
d, J¼ 7.9 Hz, 300-H), 6.98 (1H, td, J¼ 7.9, 1.4 Hz, 500-H), 7.36 (1H, td,
J¼ 7.9, 1.4 Hz, 400-H), 7.43 (1H, dd, J¼ 7.9, 1.4 Hz, 600-H); 13C NMR
(101MHz, CDCl3) d 13.9 (CH3), 20.0 (2 CH3), 27.0 (CH3), 28.4 (CH),
55.5 (CH3), 56.1 (CH2), 61.8 (CH2), 111.2 (CH), 113.0 (C), 119.9 (C),
120.8 (CH), 128.7 (C), 129.8 (C), 130.6 (CH), 130.9 (CH), 150.9 (C),
153.2 (C), 156.4 (C), 157.5 (C), 164.6 (C); MS (ESI) m/z 439 (MþNaþ,
100%); HRMS (ESI) calcd for C21H24N2NaO5S (MþNaþ), 439.1298,
found 439.1281.
4.2.9. 6-(400-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-N-morpholinecarboxamide
(14)
Ethyl 6-(400-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-carboxylate (10)
(0.18 g, 0.44mmol) was dissolved in ethanol (4mL) and water
(4mL) prior to the addition of 4M sodium hydroxide (1.5mL,
2.0mmol) and stirred at 80 C for 1 h. The reaction mixture was
diluted with water (10mL) and washed with diethyl ether
(2 10mL). The aqueous layer was acidified with 1M hydrochloric
acid and extracted with ethyl acetate (3 10mL). The combined
organic layers were dried (MgSO4), filtered and concentrated in
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(5mL) and N,N0-dimethylformamide (2 drops) and cooled to 0 C
prior to the addition of oxalyl chloride (0.045mL, 0.53mmol). The
reaction mixture was warmed to 40 C and stirred for 3 h. After
being cooled to room temperature, the reaction mixture was
concentrated in vacuo to yield the acid chloride, which was used
without further purification. The crude acid chloride was dissolved
in dichloromethane (5mL) and cooled to 0 C. Morpholine
(0.19mL, 2.2mmol) was added dropwise to the stirring acid chlo-
ride solution. The reaction mixture was stirred at 40 C for 18 h
under argon. The reaction mixture was cooled to room tempera-
ture, diluted in water (10mL) and extracted with dichloromethane
(3 10mL). The organic layers were combined, dried (MgSO4),
filtered and concentrated in vacuo. Purification by flash column
chromatography eluting with 60% ethyl acetate in petroleum ether
gave 6-(400-fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-N-morpholinecarboxamide
(14) (0.094 g, 48%) as a colourless oil. IR (neat) 2970 (CH), 1740 (CO),
1724 (CO), 1366, 1229, 1217 cm1; 1H NMR (400MHz, CDCl3) d 1.03
(6H, d, J¼ 5.6 Hz, CH(CH3)2), 2.31e2.40 (1H, m, 20-H), 3.05 (1H, ddd,
J¼ 8.5, 5.8, 2.4 Hz, NCHH), 3.10 (1H, ddd, J¼ 10.6, 4.6, 2.4 Hz,
NCHH), 3.26 (1H, ddd, J¼ 10.6, 5.8, 2.4 Hz, NCHH), 3.41 (3H, s, 3-
CH3), 3.47e3.57 (2H, m, NCHH and OCHH), 3.68 (1H, dd, J¼ 11.4,
6.0 Hz, 10-HH), 3.74e3.86 (3H, m, OCHH and OCH2), 3.97 (1H, dd,
J¼ 11.4, 6.4 Hz, 10-HH), 7.10e7.14 (2H, m, 200-H and 600-H), 7.51e7.54
(2H, m, 300-H and 500-H); 13C NMR (101MHz, CDCl3) d 20.0 (CH3),
20.1 (CH3), 27.1 (CH3), 28.3 (CH), 42.3 (CH2), 47.0 (CH2), 56.5 (CH2),
66.2 (CH2), 66.3 (CH2), 113.9 (C), 116.4 (d, 2JCF¼ 22.3 Hz, 2 CH),
127.4 (d, 4JCF¼ 3.8 Hz, C), 128.9 (C), 129.1 (C), 129.8 (d, 3JCF¼ 8.2 Hz,
2 CH), 150.7 (C), 152.9 (C), 157.7 (C), 163.1 (d, 1JCF¼ 250.7 Hz, C),
164.0 (C); MS (ESI) m/z 468 (MþNaþ, 100%); HRMS (ESI) calcd for
C22H24FN3NaO4S (MþNaþ), 468.1364, found 468.1350.
4.2.10. 6-(200-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-N-morpholinecarboxamide
(15)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 6-(200-fluo-
rophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (11) (0.178 g, 0.440mmol) and
morpholine (0.193mL, 2.21mmol). This gave title compound 15 as
a clear oil (0.105 g, 54%). IR (neat) 2961 (CH), 1707 (CO), 1663 (CO),
1489, 1113, 1001, 762 cm1; 1H NMR (400MHz, CDCl3) d 1.02 (3H, d,
J¼ 5.6 Hz, CH(CH3)), 1.02 (3H, d, J¼ 5.2 Hz, CH(CH3)), 2.30e2.40
(1H, m, 20-H), 3.04 (1H, ddd, J¼ 8.8, 6.0, 2.4 Hz, NCHH), 3.16 (1H,
ddd, J¼ 10.6, 4.4, 2.4 Hz, NCHH), 3.29 (1H, ddd, J¼ 10.6, 6.0, 2.4 Hz,
NCHH), 3.42 (3H, s, 3-CH3), 3.43e3.47 (1H, m, OCHH), 3.56 (1H, ddd,
J¼ 8.8, 4.4, 2.4 Hz, NCHH), 3.65e3.74 (2H, m, OCHH and 10-HH),
3.77e3.84 (2H, m, OCH2), 3.97 (1H, dd, J¼ 11.2, 6.4 Hz, 10-HH),
7.15e7.20 (1H, m, 600-H), 7.22 (1H, td, J¼ 7.7, 1.3 Hz, 400-H), 7.38e7.42
(1H, m, 300-H), 7.65 (1H, td, J¼ 7.7, 1.3 Hz, 500-H); 13C NMR (101MHz,
CDCl3) d 20.0 (CH3), 20.1 (CH3), 27.1 (CH3), 28.3 (CH), 42.2 (CH2),
47.0 (CH2), 56.4 (CH2), 66.2 (CH2), 66.3 (CH2), 113.1 (C), 116.0 (d,
2JCF¼ 22.7 Hz, CH), 118.7 (d, 2JCF¼ 14.5 Hz, C), 123.2 (C), 124.9 (d,
4JCF¼ 3.8 Hz, CH), 131.2 (d, 3JCF¼ 8.3 Hz, CH), 131.5 (C), 131.5 (d,
3JCF¼ 9.3 Hz, CH), 150.8 (C), 154.2 (C), 157.6 (C), 159.4 (d,
1JCF¼ 252.8 Hz, C), 163.6 (C); MS (EI) m/z 445 (Mþ, 62%), 402 (39),
359 (100), 303 (52), 276 (22), 246 (21), 190 (16), 86 (63); HRMS (EI)
calcd for C22H24FN3O4S (Mþ), 445.1472, found 445.1490.
4.2.11. 1-Isobutyl-6-(400-methoxyphenyl)-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-
morpholinecarboxamide (16)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 6-(400-methoxyphenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahy-
drothieno[2,3-d]pyrimidine-5-carboxylate (12) (0.20 g, 0.48mmol)
and morpholine (0.21mL, 2.4mmol). This gave title compound 16
(0.11 g, 48%) as a colourless oil. IR (neat) 2961 (CH), 1738 (CO), 1703
(CO), 1659 (CO), 1535 (C]C), 1485, 1252, 1113, 729 cm1; 1H NMR
(400MHz, CDCl3) d 1.02 (6H, d, J¼ 6.8 Hz, CH(CH3)2), 2.29e2.41
(1H, m, 20-H), 3.00 (1H, ddd, J¼ 10.8, 7.2, 2.8 Hz, NCHH), 3.12 (1H,
ddd, J¼ 13.2, 5.2, 2.8 Hz, NCHH), 3.26 (1H, ddd, J¼ 13.2, 7.6, 3.2 Hz,
NCHH), 3.40 (3H, s, 3-CH3), 3.47e3.54 (2H, m, NCHH and OCHH),
3.67 (1H, dd, J¼ 14.2, 7.6 Hz,10-HH), 3.72e3.90 (6H, m, OCHH, OCH2
and 400-OCH3), 3.94 (1H, dd, J¼ 14.2, 7.6 Hz, 10-HH), 6.93 (2H, d,
J¼ 8.8 Hz, 300-H and 500-H), 7.46 (2H, d, J¼ 8.8 Hz, 200-H and 600-H);
13C NMR (101MHz, CDCl3) d 20.0 (CH3), 20.1 (CH3), 27.1 (CH3), 28.3
(CH), 42.2 (CH2), 47.0 (CH2), 55.4 (CH3), 56.4 (CH2), 66.2 (CH2), 66.3
(CH2), 113.9 (C), 114.6 (2 CH), 123.6 (C), 127.6 (C), 129.2 (2 CH),
130.5 (C), 150.7 (C), 152.4 (C), 157.6 (C), 160.3 (C), 164.3 (C); MS (ESI)
m/z 480 (MþNaþ, 100%); HRMS (ESI) calcd for C23H27N3NaO5S
(MþNaþ), 480.1564, found 480.1546.
4.2.12. 1-Isobutyl-6-(200-methoxyphenyl)-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-
morpholinecarboxamide (17)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 1-isobutyl-6-(200-
methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (13) (0.18 g, 0.44mmol) and
morpholine (0.19mL, 2.2mmol). This gave title compound 17
(0.082 g, 41%) as a colourless oil. IR (neat) 2961 (CH), 1705 (CO),
1661 (CO), 1532 (C]C), 1489, 1256, 1113, 731 cm1; 1H NMR
(400MHz, CDCl3) d 1.02 (3H, d, J¼ 6.7 Hz, CH(CH3)2), 2.28e2.42
(1H, m, 20-H), 2.84 (1H, ddd, J¼ 10.4, 7.6, 2.8 Hz, NCHH), 3.15 (1H,
ddd, J¼ 13.2, 5.2, 3.2 Hz, NCHH), 3.26 (1H, ddd, J¼ 13.2, 6.4, 2.8 Hz,
NCHH), 3.36 (1H, ddd, J¼ 10.4, 7.6, 2.8 Hz, NCHH), 3.40 (3H, s, 3-
CH3), 3.48 (1H, ddd, J¼ 11.4, 7.6, 2.8 Hz, OCHH), 3.59e3.67 (2H, m,
OCHH and 10-HH), 3.76 (1H, ddd, J¼ 11.4, 6.4, 3.2 Hz, OCHH),
3.81e3.87 (4H, m, OCHH and 200-OCH3), 4.01 (1H, dd, J¼ 14.0,
8.0 Hz, 10-HH), 6.97 (1H, br d, J¼ 7.9 Hz, 300-H), 7.01 (1H, td, J¼ 7.9,
1.4 Hz, 500-H), 7.38 (1H, td, J¼ 7.9, 1.4 Hz, 400-H), 7.58 (1H, dd, J¼ 7.9,
1.4 Hz, 600-H); 13C NMR (101MHz, CDCl3) d 20.0 (CH3), 20.2 (CH3),
27.1 (CH3), 28.2 (CH), 42.2 (CH2), 47.0 (CH2), 55.6 (CH3), 56.1 (CH2),
66.3 (CH2), 66.3 (CH2), 111.0 (CH), 112.7 (C), 119.7 (C), 121.3 (CH),
126.7 (C), 130.1 (C), 130.8 (CH), 131.4 (CH), 150.9 (C), 154.1 (C), 156.2
(C), 157.7 (C), 164.1 (C); MS (ESI) m/z 480 (MþNaþ, 100%); HRMS
(ESI) calcd for C23H27N3NaO5S (MþNaþ), 480.1564, found 480.1544.
4.2.13. 6-(400-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-N-diethylcarboxamide (18)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 6-(400-fluo-
rophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (10) (0.12 g, 0.30mmol) and
diethylamine (0.16mL, 1.5mmol). This gave title compound 18
(0.040 g, 31%) as a colourless oil. IR (neat) 2963 (CH), 1707 (CO),
1665 (CO), 1636 (CO), 1533 (C]C), 1487, 1294, 1238, 841 cm1; 1H
NMR (400MHz, CDCl3) d 0.80 (3H, t, J¼ 7.2 Hz, NCH2CH3), 1.02 (3H,
d, J¼ 6.4 Hz, CH(CH3)), 1.03 (3H, d, J¼ 6.8 Hz, CH(CH3)), 1.21 (3H, t,
J¼ 7.2 Hz, NCH2CH3), 2.30e2.41 (1H, m, 20-H), 3.03e3.14 (2H, m,
NCH2CH3), 3.40 (3H, s, 3-CH3), 3.43e3.52 (1H, m, NCHHCH3),
3.60e3.71 (2H, m, NCHHCH3 and 10-HH), 3.96 (1H, dd, J¼ 14.0,
7.6 Hz, 10-HH), 7.06e7.10 (2H, m, 200-H and 600-H), 7.54e7.58 (2H, m,
300-H and 500-H); 13C NMR (101MHz, CDCl3) d 12.2 (CH3), 13.5 (CH3),
20.0 (CH3), 20.1 (CH3), 27.1 (CH3), 28.3 (CH), 39.2 (CH2), 43.0 (CH2)
56.4 (CH2), 114.0 (C), 116.1 (d, 2JCF¼ 21.6 Hz, 2 CH), 127.8 (d,
4JCF¼ 3.8 Hz, C), 128.4 (C), 129.8 (d, 3JCF¼ 9.8 Hz, 2 CH), 130.3 (C),
150.8 (C), 152.7 (C), 157.6 (C), 162.8 (d, 1JCF¼ 250.7 Hz, C), 164.7 (C);
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C22H26FN3NaO3S (MþNaþ), 454.1571, found 454.1560.
4.2.14. 6-(200-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-N-diethylcarboxamide (19)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 6-(200-fluo-
rophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (11) (0.178 g, 0.440mmol) and
diethylamine (0.228mL, 2.20mmol). This gave title compound 19
(0.0710 g, 38%) as a colourless oil. IR (neat) 2961 (CH), 1707 (CO),
1663 (CO), 1643 (CO), 1533 (C]C), 1485, 1227, 1113, 839 cm1; 1H
NMR (400MHz, CDCl3) d 0.82 (3H, t, J¼ 7.2 Hz, NCH2CH3), 1.02 (3H,
d, J¼ 6.8 Hz, CH(CH3)), 1.03 (3H, d, J¼ 6.4 Hz, CH(CH3)), 1.14 (3H, t,
J¼ 7.2 Hz, NCH2CH3), 2.32e2.40 (1H, m, 20-H), 3.03e3.17 (2H, m,
NCH2CH3), 3.34e3.43 (4H, m, 3-CH3 and NCHHCH3), 3.59e3.70 (2H,
m, NCHHCH3 and 10-HH), 4.00 (1H, dd, J¼ 14.0, 8.0 Hz, 10-HH),
7.11e7.20 (2H, m, 400-H and 600-H), 7.33e7.39 (1H, m, 300-H), 7.75 (1H,
td, J¼ 7.6,1.6 Hz, 500-H); 13C NMR (101MHz, CDCl3) d 12.2 (CH3),13.4
(CH3), 20.0 (CH3), 20.2 (CH3), 27.0 (CH3), 28.3 (CH), 39.0 (CH2), 43.0
(CH2), 56.3 (CH2), 113.1 (C), 115.7 (d, 2JCF¼ 21.7 Hz, CH), 119.1 (d,
2JCF¼ 15.1 Hz, C), 122.3 (C), 124.7 (d, 4JCF¼ 3.9 Hz, CH), 130.7 (d,
3JCF¼ 8.4 Hz, CH), 131.7 (d, 3JCF¼ 9.8 Hz, CH), 132.7 (C), 150.9 (C),
154.1 (C), 157.6 (C), 158.9 (d, 1JCF¼ 251.9 Hz, C), 164.5 (C); MS (ESI)
m/z 454 (MþNaþ, 100%); HRMS (ESI) calcd for C22H26FN3NaO3S
(MþNaþ), 454.1571, found 454.1558.
4.2.15. 1-Isobutyl-6-(400-methoxyphenyl)-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-diethylcarboxamide
(20)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 1-isobutyl-6-(400-
methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (12) (0.083 g, 0.20mmol). This
gave title compound 20 (0.026 g, 34%) as a green oil. IR (neat) 2963
(CH), 1778 (CO), 1705 (CO), 1665 (CO), 1439, 1294, 1254, 1182 cm1;
1H NMR (400MHz, CDCl3) d 0.81 (3H, t, J¼ 7.2 Hz, NCH2CH3), 1.01
(3H, d, J¼ 6.8 Hz, CH(CH3)), 1.02 (3H, d, J¼ 6.8 Hz, CH(CH3)), 1.20
(3H, t, J¼ 7.2 Hz, NCH2CH3), 2.32e2.39 (1H, m, 20-H), 3.02e3.14 (2H,
m, NCH2CH3), 3.40 (3H, s, 3-CH3), 3.48 (1H, dt, J¼ 13.6, 7.2 Hz,
NCHHCH3), 3.61e3.70 (2H, m, NCHHCH3 and 10-HH), 3.82 (3H, s, 400-
OCH3), 3.96 (1H, dd, J¼ 14.0, 8.0 Hz, 10-HH), 6.89 (2H, d, J¼ 8.9 Hz,
300-H and 500-H), 7.49 (2H, d, J¼ 8.9 Hz, 200-H and 600-H); 13C NMR
(101MHz, CDCl3) d 12.3 (CH3), 13.5 (CH3), 20.1 (CH3), 20.2 (CH3),
27.1 (CH3), 28.3 (CH), 39.2 (CH2), 43.0 (CH2), 55.3 (CH3), 56.3 (CH2),
114.0 (C), 114.4 (2 CH), 124.1 (C), 129.0 (C), 129.2 (2 CH), 129.7
(C), 150.9 (C), 152.3 (C), 157.6 (C), 160.0 (C), 165.0 (C); MS (ESI) m/z
466 (MþNaþ, 100%); HRMS (ESI) calcd for C23H29N3NaO4S
(MþNaþ), 466.1771, found 466.1764.
4.2.16. 1-Isobutyl-6-(200-methoxyphenyl)-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-N-diethylcarboxamide
(21)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 1-isobutyl-6-(200-
methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (13) (0.182 g, 0.440mmol) and
diethylamine (0.227mL, 2.20mmol). This gave title compound 21
as a colourless oil (0.0680 g, 32%). IR (neat) 2963 (CH), 1705 (CO),
1661 (CO), 1634 (CO), 1487, 1251, 1020, 750 cm1; 1H NMR
(400MHz, CDCl3) d 0.78 (3H, t, J¼ 7.2 Hz, NCH2CH3), 1.01 (3H, d,
J¼ 6.8 Hz, CH(CH3)), 1.02 (3H, d, J¼ 6.8 Hz, CH(CH3)), 1.11 (3H, t,
J¼ 7.2 Hz, NCH2CH3), 2.30e2.41 (1H, m, 20-H), 3.00e3.19 (2H, m,
NCH2CH3), 3.31e3.43 (4H, m, 3-CH3 and NCHHCH3), 3.59e3.68 (2H,
m, NCHHCH3 and 10-HH), 3.88 (3H, s, 200-OCH3), 4.03 (1H, dd,J¼ 14.0, 8.0 Hz, 10-HH), 6.92e6.99 (2H, m, 300-H and 500-H), 7.33 (1H,
td, J¼ 7.8, 1.6 Hz, 400-H), 7.68 (1H, dd, J¼ 7.8, 1.6 Hz, 600-H); 13C NMR
(101MHz, CDCl3) d 12.2 (CH3),13.4 (CH3), 20.0 (CH3), 20.2 (CH3) 27.1
(CH3), 28.2 (CH), 39.0 (CH2), 42.9 (CH3) 55.6 (CH2), 56.1 (CH2), 110.8
(CH), 112.7 (C), 120.1 (C), 121.1 (CH), 125.7 (C), 130.3 (CH), 131.5 (CH
and C), 151.0 (C), 154.0 (C), 156.0 (C), 157.7 (C), 165.0 (C); MS (EI)m/z
443 (Mþ, 75%), 371 (28), 344 (8), 315 (19), 230 (9), 155 (7), 117 (9),
105 (12), 84 (82), 72 (100); HRMS (EI) calcd for C23H29N3O4S (Mþ),
443.1879, found 443.1867.
4.2.17. 6-(400-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-methyl)
carboxamide (22)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 6-(400-fluo-
rophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (10) (0.080 g, 0.20mmol) and a
combination of N,O-dimethylhydroxylamine hydrochloride
(0.064 g, 0.66mmol) and N,N0-diisopropylethylamine (0.23mL,
1.3mmol). This gave title compound 22 as a viscous yellow oil
(0.040 g, 38%). IR (neat) 2959 (CH), 1707 (CO), 1662 (CO), 1535 (C]
C), 1486, 1390, 991, 773 cm1; The compound exists as a 3:1
mixture of rotamers. Data for the major rotamer: 1H NMR
(400MHz, CDCl3) d 1.02 (6H, d, J¼ 6.8 Hz, CH(CH3)2), 2.31e2.42
(1H, m, 20-H), 3.35 (3H, s, NCH3), 3.36 (3H, s, OCH3), 3.41 (3H, s, 3-
CH3), 3.68 (1H, dd, J¼ 14.1, 7.7 Hz, 10-HH), 3.95 (1H, dd, J¼ 14.1,
7.7 Hz, 10-HH), 7.10 (2H, t, J¼ 8.8 Hz, 200-H and 600-H), 7.57 (2H, dd,
J¼ 8.8, 5.2 Hz, 300-H and 500-H); 13C NMR (101MHz, CDCl3) d 20.0
(CH3), 20.1 (CH3), 27.1 (CH3), 28.3 (CH), 33.1 (CH3), 56.5 (CH2), 61.5
(CH3), 114.4 (C), 116.3 (d, 2JCF¼ 22.2 Hz, 2 CH), 127.7 (d,
4JCF¼ 3.1 Hz, C), 128.7 (C), 129.2 (C), 129.8 (d, 3JCF¼ 8.4 Hz, 2 CH),
150.8 (C), 152.1 (C), 157.8 (C), 162.9 (d, 1JCF¼ 248.9 Hz, C), 166.4 (C);
MS (ESI) m/z 442 (MþNaþ, 100%); HRMS (ESI) calcd for
C20H22FN3NaO4S (MþNaþ), 442.1207, found 442.1191.
4.2.18. 6-(200-Fluorophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-
tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-methyl)
carboxamide (23)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 6-(200-fluo-
rophenyl)-1-isobutyl-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (11) (0.070 g, 0.17mmol) and a
combination of N,O-dimethylhydroxylamine hydrochloride
(0.017 g, 0.18mmol) and N,N0-diisopropylethylamine (0.080mL,
0.48mmol). This gave title compound 23 as a viscous yellow oil
(0.038 g, 57%). IR (neat) 2970 (CH), 1740 (CO), 1728 (CO), 1663 (CO),
1533 (C]C), 1366, 1217, 1119, 991 cm1; The compound exists as a
3:1 mixture of rotamers. Data for the major rotamer: 1H NMR
(400MHz, CDCl3) d 1.02 (6H, d, J¼ 6.7 Hz, CH(CH3)2), 2.31e2.41 (1H,
m, 20-H), 3.32 (3H, s, NCH3), 3.37 (3H, s, OCH3), 3.42 (3H, s, 3-CH3),
3.68 (1H, dd, J¼ 14.1, 7.5 Hz, 10-HH), 3.97 (1H, dd, J¼ 14.1, 7.5 Hz, 10-
HH), 7.13e7.22 (2H, m, 400-H and 600-H), 7.33e7.41 (1H, m, 300-H),
7.72 (1H, td, J¼ 8.0, 1.6 Hz, 500-H); 13C NMR (101MHz, CDCl3) d 20.0
(CH3), 20.1 (CH3), 27.0 (CH3), 28.3 (CH), 33.1 (CH3), 56.3 (CH2), 61.4
(CH3), 113.5 (C), 115.9 (d, 2JCF¼ 21.8 Hz, CH), 119.2 (d, 2JCF¼ 14.0 Hz,
C), 123.2 (C), 124.8 (d, 3JCF¼ 3.5 Hz, CH), 130.8 (d, 3JCF¼ 9.0 Hz, CH),
131.1 (C), 131.5 (d, 2JCF¼ 2.8 Hz, CH), 150.7 (C), 153.4 (C), 157.7 (C),
159.3 (d, 1JCF¼ 250.4 Hz, C), 166.1 (C); MS (ESI) m/z 442 (MþNaþ,
100%); HRMS (ESI) calcd for C20H22FN3NaO4S (MþNaþ), 442.1207,
found 442.1191.
4.2.19. 1-Isobutyl-6-(400-methoxyphenyl)-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-
methyl)carboxamide (24)
The reaction was carried out according to the previously
K.M. O'Rourke et al. / Tetrahedron 74 (2018) 4086e40944094described procedure for compound 14 using ethyl 1-isobutyl-6-(400-
methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (12) (0.296 g, 0.710mmol) and a
combination of N,O-dimethylhydroxylamine hydrochloride
(0.227 g, 2.32mmol) and N,N0-diisopropylethylamine (0.930mL,
4.64mmol). This gave title compound 24 as a viscous yellow oil
(0.102 g, 51%). IR (neat) 2961 (CH), 1705 (CO), 1657 (CO), 1537 (C]
C), 1485, 1254, 1180, 733 cm1; The compound exists as a 3:1
mixture of rotamers. Data for the major rotamer: 1H NMR
(400MHz, CDCl3) d 1.02 (3H, d, J¼ 6.0 Hz, CH(CH3)2), 2.29e2.42
(1H, m, 20-H), 3.35 (3H, s, NCH3), 3.37 (3H, s, OCH3), 3.41 (3H, s, 3-
CH3), 3.68 (1H, dd, J¼ 14.1, 7.5 Hz, 10-HH), 3.83 (3H, s, 400-OCH3),
3.95 (1H, dd, J¼ 14.1, 7.5 Hz, 10-HH), 6.92 (2H, d, J¼ 8.8 Hz, 300-H and
500-H), 7.52 (2H, d, J¼ 8.8 Hz, 200-H and 600-H); 13C NMR (101MHz,
CDCl3) d 20.0 (CH3), 20.1 (CH3), 27.1 (CH3), 28.3 (CH), 33.2 (CH3),
55.4 (CH3), 56.4 (CH2), 61.5 (CH3), 114.4 (C), 114.6 (2 CH),124.0 (C),
127.5 (C), 129.2 (2 CH), 130.5 (C), 150.8 (C), 151.7 (C), 157.9 (C),
160.0 (C), 166.8 (C); MS (ESI) m/z 454 (MþNaþ, 100%); HRMS (ESI)
calcd for C21H25N3NaO5S (MþNaþ), 454.1407, found 454.1393.
4.2.20. 1-Isobutyl-6-(200-methoxyphenyl)-3-methyl-2,4-dioxo-
1,2,3,4-tetrahydrothieno[2,3-d]pyrimidine-5-(N-methoxy-N-
methyl)carboxamide (25)
The reaction was carried out according to the previously
described procedure for compound 14 using ethyl 1-isobutyl-6-(200-
methoxyphenyl)-3-methyl-2,4-dioxo-1,2,3,4-tetrahydrothieno
[2,3-d]pyrimidine-5-carboxylate (13) (0.119 g, 0.29mmol) and a
combination of N,O-dimethylhydroxylamine hydrochloride
(0.0933 g, 0.960mmol) and N,N0-diisopropylethylamine (0.334mL,
1.92mmol). This gave title compound 25 as a viscous oil (0.070 g,
56%). IR (neat) 2961 (CH), 1703 (CO), 1657 (CO), 1533 (C]C), 1489,
1252, 1123, 991, 729 cm1; The compound exists as a 3:1 mixture of
rotamers. Data for the major rotamer: 1H NMR (400MHz, CDCl3)
d 1.01 (6H, d, J¼ 6.8 Hz, CH(CH3)2), 2.29e2.41 (1H, m, 20-H), 3.31
(3H, s, NCH3), 3.34 (3H, s, OCH3), 3.41 (3H, s, 3-CH3), 3.64 (1H, dd,
J¼ 14.1, 7.7 Hz, 10-HH), 3.87 (3H, s, 200-OCH3), 4.00 (1H, dd, J¼ 14.1,
7.7 Hz, 10-HH), 6.95 (1H, d, J¼ 7.8 Hz, 300-H), 7.00 (1H, t, J¼ 7.8 Hz,
500-H), 7.34 (1H, td, J¼ 7.8, 1.6 Hz, 400-H), 7.66 (1H, dd, J¼ 7.8, 1.6 Hz,
600-H); 13C NMR (101MHz, CDCl3) d 20.0 (CH3), 20.2 (CH3), 27.1
(CH3), 28.2 (CH), 33.1 (CH3), 55.6 (CH2), 56.1 (CH3), 61.3 (CH3), 111.1
(CH), 113.0 (C), 120.3 (C), 121.2 (CH), 128.1 (C), 129.9 (C), 130.3 (CH),
131.2 (CH),151.0 (C),153.3 (C),156.1 (C),157.8 (C),166.8 (C); MS (ESI)
m/z 454 (MþNaþ, 100%); HRMS (ESI) calcd for C21H25N3NaO5S
(MþNaþ), 454.1407, found 454.1389.
4.3. Biological assay for the inhibition of lactate uptake in Xenopus
oocytes
Oocytes were injected with 5 ng of cRNA coding for MCT1,
MCT2þGP70 andMCT4, respectively. Experiments were carried out
5e7 days after injection. For each experiment, a batch of 8 oocytes
was incubated in 1 mL of uptake solution (82.5 mM NaCl, 2.5 mM
KCl, 1 mM CaCl2, 1mM MgCl2, 1mM Na2HPO4, 5mM HEPES, pH7),
containing 1 mM of inhibitor for 1 h. After incubation, the solution
was replaced with 100 mL of uptake solution, containing 0.5mM of
14C-labelled lactate (0.2 mCi). Oocytes were incubated for 2.5min.
Uptake was stopped by washing the oocytes three times with ice-
cold uptake solution. Each cell was placed into a scintillation vial
and lysed with 200 mL of 10% sodium dodecyl sulfate (SDS). After
lysis, 3mL of scintillation fluid (Rotiszint® eco plus scintillation
cocktail, Carl Roth) was added and the radioactivity determined byliquid scintillation counting using a Tri-Carb 2810 TR scintillation
counter (Perkin Elmer). To determine MCT-mediated fluxes, values
from native oocytes were subtracted from the values measured in
MCT-expressing cells. Statistical values are presented as
means ± standard error of the mean. For calculation of significance
in difference oneway analysis of variance (ANOVA) was carried out,
followed by means comparison using either Scheffe or Bonferroni
test, depending onwhether datasets show homogeneity of variance
or not. Homogeneity of variance was assessed using Levene's test.
All statistical tests were carried out with OriginPro 8.6. In the fig-
ures shown, a significance level of p  0.05 is marked with *,
p  0.01 with **, and p  0.001 with ***.Acknowledgements
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